Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2003

View Archived Issues

Novel dopamine autoreceptor partial agonists designed at Wyeth

Millennium claims novel CCR5 modulators and their use in HIV infection

New IL-4 production inhibitors identified by Mitsubishi Pharma researchers

Dual TXA2/5-HT2 antagonists prepared and tested by Servier research team

Antiallergic benzopyrans in early development at Japanese lab

Ono presents novel PPARalpha/PPARgamma agonists for diabetes and lipoprotein disorders

Morishita Jintan claims plant extracts with antidiabetic activity

Evidence of antiretroviral activity reported for amdoxovir in treatment-experienced patients

Lower serum melatonin levels reported in patients with HIV-1 infection

Good pregnancy rates reported with ganirelix in IVF/ICSI

Pharmacokinetics, efficacy and safety data presented for enfuvirtide

New data on the efficacy and safety of emtricitabine therapy in HIV infection

Genesis Bioventures and Innathera sign business combination agreement

AstraZeneca submits data to support Crestor NDA

Merck and MerLion enter drug discovery alliance

Albany Molecular Research enters natural products collaboration with Lilly

Phase II trial commences for Aquavan

BioMS makes plans for phase I trial of HYC-750

Endovasc sponsors preliminary Liprostin study

Phase I StemEx trial begins patient enrollment

Repligen studies triacetyluridine for mitochondrial disease in new phase I/II trial

FluINsure generates encouraging data in challenge study

DX-88 granted orphan drug designation by FDA

CAT reports first-quarter update

NBI-42902 well tolerated and effective in postmenopausal women

Nonpeptide GnRH antagonist shows rapid, long-lasting oral activity in humans

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...